The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Means for STEM competence for pre- and post-test. حسب Esther Kim (2996622)

الموضوعات:

Means for global competence pre- and post-test scores. حسب Esther Kim (2996622)

الموضوعات:

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. حسب Xiaoqin Li (1399105)

Decadal mean regional hydrology. حسب Nic Gedney (19762301)

الموضوعات:

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Simulated regional mean wetland seasons. حسب Nic Gedney (19762301)

الموضوعات:

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. حسب Guihua Wang (286390)

Claudin V is decreased following infection with Mtb. حسب Amanda S. Latham (12093638)

"…Exposure to Mtb H37Rv and HN878 decreased claudin V expression compared to uninfected controls in the frontal cortex (E), cerebral nuclei (J), brain stem (O), thalamus (T), and hippocampus (Y). …"

Contemporary mean inundation fraction in the Amazon basin. حسب Nic Gedney (19762301)

الموضوعات:

Regional contemporary (1990–1999 mean) precipitation and JULES inundation fraction over the Amazon basin. حسب Nic Gedney (19762301)

الموضوعات:

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. حسب Daisuke Sugahara (2047696)

Trends of growth stability index (A), mean productivity index (B), stress tolerance index (C), and harmonic mean (D). حسب Nadia Khater (22553166)

الموضوعات:

Soluble sugar content in the stem (A), Soluble sugar content in the root (B), Amino acids content in the stem (C), Amino acids content in the root (D), and proline concentration (E... حسب Nadia Khater (22553166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: